Somite.ai

AI-based Platform to Produce Human Tissue for Cell-based Therapies

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in October 2023 by Micha Breakstone, Olivier Pourquie, Jay Shendure, Allon Klein, Cliff Tabin, and Jonathan Rosenfeld, Somite.ai operates with 11–50 employees. The company has raised $57.5 million across 3 funding rounds from 16 investors, with Khosla Ventures leading a significant Series A round in May 2025.

Business overview

Somite.ai is developing an AI-driven platform to produce human tissue for cell therapies at scale, addressing diseases such as diabetes, obesity, and muscular dystrophies. Its core technology, AlphaStem (also referred to as DeltaStem), leverages AI foundation models to enable new cell therapies and generate data for continuous platform improvement. The company's pipeline includes programs like SMT-M01 for Duchenne muscular dystrophy (DMD) and SMT-B01 for metabolic disorders, serving the Health Tech & Life Sciences sector, specifically in Pharma &.

Strategic signal

In May 2025, Somite AI secured a Series A funding round led by. This investment validates the company's AI-driven approach to cell therapy and will accelerate the development of its DeltaStem platform and therapeutic programs, signaling strong investor confidence in its potential to revolutionize regenerative medicine.

Log in to access full profile

Company Intelligence Q&A

What was the most recent funding round for Somite.ai?
In May 2025, Somite.ai completed a Series A funding round led by Khosla Ventures.
What is Somite.ai's primary technological focus?
Somite.ai focuses on developing AI foundation models to produce human tissue for cell therapies, utilizing its AlphaStem/DeltaStem platform to enable and accelerate therapy creation.
Which diseases is Somite.ai targeting with its cell therapies?
Somite.ai is targeting diseases such as diabetes, obesity, muscular dystrophies, and blood disorders with its cell therapy programs, including SMT-M01 for Duchenne muscular dystrophy (DMD) and SMT-B01 for metabolic disorders.
When was Somite.ai founded and by whom?
Somite.ai was founded in October 2023 by Micha Breakstone, Olivier Pourquie, Jay Shendure, Allon Klein, Cliff Tabin, and Jonathan Rosenfeld.
Has Somite.ai made any recent executive appointments?
In September 2024, Somite.ai appointed Shai Kivity as its VP of Strategy & Operations. Additionally, in May 2025, Fidji Simo was appointed as CEO of Applications and Board Member.
Log in to access full profile